PRODUCT MONOGRAPH

Pr HYDREA®

(hydroxyurea)

Capsules USP, 500 mg

Antineoplastic Agent

Bristol-Myers Squibb Canada
Montreal, Canada

Control No.: 206452

Date of Preparation: March 23, 1979
Date of Revision: September 26, 2017

HYDREA is a registered trademark of Bristol-Myers Squibb Canada Co.
PRODUCT MONOGRAPH
HYDREA®
(hydroxyurea)
Capsules USP, 500 mg

THERAPEUTIC CLASSIFICATION
Antineoplastic Agent

HYDREA (HYDROXYUREA) SHOULD BE ADMINISTERED UNDER THE SUPERVISION OF A PHYSICIAN EXPERIENCED IN THE USE OF CANCER CHEMOTHERAPEUTIC AGENTS.

ACTIONS AND CLINICAL PHARMACOLOGY

Neoplastic Disease: The precise mechanism by which HYDREA (hydroxyurea) produces its antineoplastic effects cannot, at present, be described. However, the reports of various studies in rat and human tissue cultures lend support to the hypothesis that hydroxyurea causes an immediate inhibition of DNA synthesis, by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or of protein. Hydroxyurea probably acts by decreasing the rate of conversion of ribonucleotides and deoxyribonucleotides. This effect is particularly apparent in cells with a high rate of proliferation.

Potentiation of Irradiation Therapy: Three mechanisms have been postulated for the potentiation of the therapeutic effects of irradiation by hydroxyurea on squamous cell (epidermoid) carcinomas of the head and neck. In vitro studies utilizing Chinese hamster cells suggest that hydroxyurea is lethal to normally radioresistant S-stage cells and holds other cells of the cell cycle in the G1 or pre-DNA synthesis stage where they are most susceptible to the effects of irradiation. The third mechanism of action has been theorized on the basis of in vitro studies of HeLa cells: it appears that hydroxyurea, by inhibition of DNA synthesis, hinders the normal repair process of cells damaged but not killed by irradiation, thereby decreasing their survival rate; there is no alteration of RNA and protein syntheses.

Pharmacokinetics

Absorption: Hydroxyurea is readily absorbed after oral administration. Peak plasma levels are reached in 1-4 hours after an oral dose. With increasing doses, disproportionately greater mean peak plasma concentrations and area under the plasma concentration-time curve (AUC) are observed. There are no data on the effect of food on the absorption of hydroxyurea.

Distribution: Hydroxyurea distributes rapidly and widely in the body with an estimated volume of distribution approximating total body water. Plasma to ascites fluid ratios range from 2:1 to 7.5:1. Hydroxyurea concentrates in leukocytes and erythrocytes. Hydroxyurea crosses the blood-
Metabolism: Up to 50% of an oral dose undergoes conversion through metabolic pathways that are not fully characterized. In one minor pathway, hydroxyurea may be degraded to acetohydroxamic acid by urease found in intestinal bacteria.

Excretion: Excretion of hydroxyurea in humans is a nonlinear process occurring through two pathways: one is saturable, probably hepatic metabolism; the other is first-order renal excretion. In patients with malignancies, renal elimination ranged from 25-55% of the administered dose. The concentration in the serum at 24 hours is negligible when the usual dose is given as a single daily dose.

Special Populations: No information is available regarding pharmacokinetic differences due to age, gender, or race.

Renal Insufficiency: Since renal excretion is a pathway of elimination, consideration should be given to decreasing the dosage in this population. In adult patients with sickle cell disease, an open-label, non-randomized, single dose, multi-center study was conducted to assess the influence of renal function on the pharmacokinetics of hydroxyurea. Patients in the study with normal (creatinine clearance (CrCl) > 80 ml/min), mild (CrCl 50-80 ml/min), or severe (CrCl < 30 ml/min) renal impairment received hydroxyurea as a single oral dose of 15 mg/kg, achieved by using combinations of the 200 mg, 300 mg, or 400 mg capsules. Patients with end-stage renal disease (ESRD) received two doses of 15 mg/kg separated by 7 days, the first was given following a 4-hour hemodialysis session, the second prior to hemodialysis. In this study the mean exposure (AUC) in patients whose creatinine clearance was < 60 ml/min (or ESRD) was approximately 64% higher than in patients with normal renal function. The results suggest that the initial dose of hydroxyurea should be reduced when used to treat patients with renal impairment (see PRECAUTIONS and DOSAGE AND ADMINISTRATION).

Hepatic Insufficiency: There are no data that support specific guidance for dosage adjustment in patients with impaired hepatic function (see DOSAGE AND ADMINISTRATION).

INDICATIONS AND CLINICAL USE

HYDREA (hydroxyurea) is indicated for concomitant use with irradiation therapy in the treatment of primary squamous cell (epidermoid) carcinomas of the head and neck, excluding the lip.

Tumor responses to HYDREA have been reported in melanoma and resistant chronic myelocytic leukemia.

CONTRAINDICATIONS

HYDREA (hydroxyurea) is contraindicated in patients with marked bone marrow depression, i.e., leukopenia (< 2500 WBC/mm³) or thrombocytopenia (< 100,000/mm³), or severe anemia; or in patients who have demonstrated a previous hypersensitivity to hydroxyurea or any other component of its formulation.

WARNINGS

HYDREA (hydroxyurea) should be administered under the supervision of a physician
experienced in the use of cancer chemotherapeutic agents.

Treatment with HYDREA should not be initiated if bone marrow function is depressed (see CONTRAINDICATIONS). HYDREA may produce bone marrow suppression; leukopenia is generally its first and most common manifestation. Thrombocytopenia and anemia occur less often and are seldom seen without a preceding leukopenia. The recovery from myelosuppression is rapid when HYDREA therapy is interrupted. Bone marrow depression is more likely in patients who have previously received radiotherapy or cytotoxic cancer chemotherapeutic agents; HYDREA should be used cautiously in such patients.

Severe anemia must be corrected before initiating therapy with HYDREA.

Erythrocytic abnormalities: megaloblastic erythropoiesis, which is self-limiting, is often seen early in the course of HYDREA therapy. The morphologic change resembles that seen in pernicious anemia, but is not related to vitamin B12 or folic acid deficiency. The macrocytosis may mask the incidental development of folic acid deficiency; regular determinations of serum folic acid are recommended. Hydroxyurea may also delay plasma iron clearance and reduce the rate of iron utilization by erythrocytes, but it does not appear to alter the red blood cell survival time.

Patients who have received irradiation therapy in the past may have an exacerbation of post irradiation erythema when HYDREA is given.

Geriatric Use
Elderly patients may be more sensitive to the effects of HYDREA and may require a lower dose regimen.

Carcinogenesis, Mutagenesis, Impairment of Fertility
Hydroxyurea is unequivocally genotoxic and a presumed transpecies carcinogen which implies a carcinogenic risk to humans. In patients receiving long-term therapy with hydroxyurea for myeloproliferative disorders, such as polycythemia vera and thrombocytopenia, secondary leukemia has been reported. It is unknown whether this leukemogenic effect is secondary to hydroxyurea or is associated with the patients’ underlying disease. Skin cancer has also been reported in patients receiving long-term hydroxyurea.

Azoospermia or oligospermia, sometimes reversible, have been observed in men. Male patients should be informed about the possibility of sperm conservation before the start of therapy.

As hydroxyurea is genotoxic, men under therapy are advised to use safe contraceptive measures during and at least 1 year after therapy.

Use in Pregnancy
Hydroxyurea has been demonstrated to be a potent teratogen in a wide variety of animal models, including mice, rats, hamsters, rabbits, cats, miniature swine, dogs, and monkeys. The spectrum of effects following prenatal exposure to hydroxyurea includes embryo-fetal death, numerous
fetal malformations of the viscera and skeleton, growth retardation, and functional deficits.

HYDREA can cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies in pregnant women. If HYDREA is used during pregnancy or if the patient becomes pregnant while on HYDREA therapy, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant while taking HYDREA.

HYDREA should not be used to treat males contemplating conception.

**Vaccinations**

Concomitant use of HYDREA with a live virus vaccine may potentiate the replication of the vaccine virus because normal defense mechanisms may be suppressed by HYDREA. Vaccination with a live vaccine in a patient taking HYDREA may result in severe infection. Patient’s antibody response to vaccines, including killed or inactivated vaccines, may be suboptimal. The use of live vaccines should be avoided and individual specialist advice sought (see DRUG INTERACTIONS).

**Drug-induced Fever**

High fever (≥39°C) requiring hospitalization has been reported, in some cases concurrently with gastrointestinal, pulmonary, musculoskeletal, hepatobiliary, dermatological or cardiovascular manifestations. Onset typically occurred within 6 weeks of initiation and resolved promptly after discontinuation of hydroxyurea. Upon re-administration fever re-occurred within 24 hours.

**Hepatic**

Hepatitis and cholestasis have been reported commonly in patients treated with HYDREA, with many requiring hospitalization. If hepatitis or cholestasis occurs, HYDREA should be discontinued (see ADVERSE EVENTS).

Hepatotoxicity and hepatic failure resulting in death were reported during postmarketing surveillance in HIV-infected patients treated with hydroxyurea and other antiretroviral agents. Fatal hepatic events were reported most often in patients treated with the combination of hydroxyurea, didanosine, and stavudine. This combination should be avoided.

**Tumor Lysis Syndrome**

Tumor lysis syndrome has been reported in patients taking HYDREA therapy. Patients at risk of tumor lysis syndrome are those with the highest tumor burden prior to treatment. Monitor patients closely and take appropriate precautions.

**Other**

Fatal and nonfatal pancreatitis has occurred in HIV-infected patients during therapy with
hydroxyurea and didanosine, with or without stavudine. This combination should be avoided.

Peripheral neuropathy, which was severe in some cases, has been reported in HIV-infected patients receiving hydroxyurea in combination with antiretroviral agents, including didanosine, with or without stavudine (see ADVERSE EVENTS).

Cutaneous vasculitic toxicities including vasculitic ulcerations and gangrene have occurred in patients with myeloproliferative disorders during therapy with hydroxyurea. These vasculitic toxicities were reported most often in patients with a history of or currently receiving interferon therapy. Due to potentially severe clinical outcomes for the cutaneous vasculitic ulcers reported in patients with myeloproliferative disease, hydroxyurea should be discontinued if cutaneous vasculitic ulcerations develop and alternative cytoreductive agents should be initiated as indicated (see ADVERSE EVENTS: Dermatologic).

**PRECAUTIONS**

**Renal Insufficiency**

HYDREA (hydroxyurea) should be used with caution in patients with renal dysfunction (see DOSAGE and ADMINISTRATION).

**Use in Children**

Safety and effectiveness of HYDREA in children have not been established.

**Nursing Mothers**

Hydroxyurea is secreted in human milk. Because of the potential for serious adverse reactions in nursing infants from hydroxyurea, breast feeding should be discontinued.

**Drug Interactions**

Prospective studies on the potential for hydroxyurea to interact with other drugs have not been performed.

Concurrent use of hydroxyurea and other myelosuppressive agents or radiation therapy may increase the likelihood of bone marrow depression or other adverse events (see WARNINGS and ADVERSE REACTIONS).

Since hydroxyurea may raise the serum uric acid level, dosage adjustment of uricosuric medication may be necessary.

A published study has shown increases of laboratory values of urea, uric acid (5-9%) and lactic acid (6-11%) measured by *in vitro* enzymatic assays, in the presence of hydroxyurea (0.1 – 1 mM), indicating an analytical interference. The clinical relevance of these results is unknown.

*In vitro* studies have shown a significant increase in cytarabine cytotoxic activity in hydroxyurea-treated cells. Whether this interaction will lead to synergistic toxicity in the clinical
setting or the need to modify cytarabine doses has not been established.

There is increased risk of serious and fatal infections with the concomitant use of live vaccines.
Live vaccines are not recommended in patients treated with HYDREA (see WARNINGS - Vaccinations).

**Driving/Operating Machinery**
The effect of HYDREA on driving and operating machinery has not been studied. Since HYDREA may cause drowsiness and other neurologic effects (see ADVERSE REACTIONS, Neurologic), alertness may be impaired.

**Information for Patients**
Patients should be informed to maintain adequate fluid intake. The physician should be consulted regarding missed doses.

**ADVERSE REACTIONS**

**Hematologic**
Bone marrow depression (leukopenia, anemia, and occasionally thrombocytopenia) (see WARNINGS).

**Gastrointestinal**
Stomatitis, anorexia, nausea, vomiting, diarrhea, and constipation.

**Dermatologic**
Maculopapular rash, facial erythema, peripheral erythema, skin ulceration and dermatomyositis-like skin changes. Nail pigmentation (melanonychia) has been observed in some patients. Hyperpigmentation, erythema, atrophy of skin and nails, scaling, violet papules, and alopecia have been observed in some patients after several years of long-term daily maintenance therapy with HYDREA. Skin cancer has been reported rarely.

Cutaneous vasculitic toxicities including vasculitic ulcerations and gangrene have occurred in patients with myeloproliferative disorders during therapy with hydroxyurea. These vasculitic toxicities were reported most often in patients with a history of or currently receiving interferon therapy (see WARNINGS).

**Neurologic**
Drowsiness, rare instances of headache, dizziness, disorientation, hallucinations, and convulsions. Their relationship to hydroxyurea administration is questionable because cerebral
metastatic disease was not excluded.

Renal
Elevated serum uric acid, BUN, and creatinine levels; rare instances of dysuria. Abnormal BSP retention has been reported.

Hepatic
Hepatitis and cholestasis have been reported commonly in patients treated with HYDREA with many requiring hospitalization. If hepatitis or cholestasis occurs HYDREA should be discontinued. Elevation of hepatic enzymes have been reported.

Fatal and nonfatal hepatotoxicity have been reported in HIV-infected patients who received hydroxyurea in combination with antiretroviral agents, in particular didanosine plus stavudine.

Other
Fever, chills, malaise, asthenia, azoospermia, oligospermia, tumor lysis syndrome and rare instances of acute pulmonary reactions (diffuse pulmonary infiltrates/fibrosis, and dyspnea). Fatal and nonfatal pancreatitis and severe peripheral neuropathy have been reported in HIV-infected patients who received hydroxyurea in combination with antiretroviral agents, in particular didanosine plus stavudine. Patients treated with hydroxyurea in combination with didanosine, stavudine, and indinavir in study ACTG 5025 showed a median decline in CD4 cells of approximately 100/mm³ (see WARNINGS).

Combined HYDREA and Irradiation Therapy
Adverse reactions observed with combined HYDREA and irradiation therapy were similar to those reported with the use of HYDREA alone, primarily bone marrow depression (leukopenia and anemia), and gastric irritation. Nearly all patients receiving an adequate course of combined HYDREA and irradiation therapy will develop leukopenia. Decreased platelet counts (< 100,000 cells/mm³) have occurred rarely and usually in the presence of marked leukopenia. HYDREA may potentiate some adverse reactions usually seen with irradiation alone, such as gastric distress and mucositis.

SYMPTOMS AND TREATMENT OF OVERDOSAGE
For management of a suspected drug overdose, contact your regional Poison Control Centre.
Acute mucocutaneous toxicity has been reported in patients receiving hydroxyurea at a dosage several times the therapeutic dose. Soreness, violet erythema, edema on palms and foot soles followed by scaling of hands and feet, severe generalized hyperpigmentation of skin, and stomatitis have also been observed.

**DOSAGE AND ADMINISTRATION**

Because of the rarity of carcinomas of the head and neck in children, dosage regimens have not been established.

Dosage regimens in the treatment of the neoplastic diseases should be based on the patient's actual or ideal weight, whichever is less.

**Solid Tumors**

*Intermittent Therapy:* 80 mg/kg administered orally as a *single* dose every *third* day.

This intermittent dosage schedule may offer the advantage of reduced toxicity over daily therapy (e.g., bone marrow depression).

*Concomitant Therapy with Irradiation* (Carcinoma of the head and neck): 80 mg/kg administered orally as a *single* dose every *third* day.

Administration of HYDREA (hydroxyurea) should be started at least seven days before initiation of irradiation, and continued during radiotherapy and continue indefinitely thereafter, provided the patient is kept under adequate observation and exhibits no unusual or severe toxicity.

**Resistant Chronic Myelocytic Leukemia**

*Continuous Therapy*

20 to 30 mg/kg administered orally as a single daily dose.

An adequate trial period for determining the effectiveness of HYDREA is 6 weeks. When there is regression in tumor size or arrest in tumor growth, therapy should be continued indefinitely. Therapy should be interrupted if the white blood cell count drops below 2500/mm³, or the platelet count below 100,000/mm³. In these cases, the counts should be reevaluated after 3 days, and therapy resumed when the counts return to acceptable levels. Hematopoietic rebound is usually rapid. If rapid rebound has not occurred during combined HYDREA and irradiation therapy, irradiation may also be interrupted. Anemia, even if severe can be managed without interrupting HYDREA therapy.

HYDREA should be administered cautiously to patients who have recently received extensive radiation therapy or chemotherapy with other cytotoxic drugs (see WARNINGS and ADVERSE EVENTS).

Pain or discomfort from inflammation of the mucous membranes at the irradiated site (mucositis) is usually controlled by measures such as topical anesthetics and orally administered analgesics. If the reaction is severe, HYDREA therapy may be temporarily interrupted; if it is extremely
severe, irradiation dosage may, in addition, be temporarily postponed.

Severe gastric distress, such as nausea, vomiting, and anorexia, resulting from combined therapy may usually be controlled by interruption of HYDREA administration.

**DOSAGE ADJUSTMENT**

Concurrent use of HYDREA with other myelosuppressive agents may require adjustments of dosages.

**Renal Insufficiency:** There are no data that support specific guidance for dosage adjustment in patients with impaired renal function. Since renal excretion is a pathway of elimination, consideration should be given to decreasing the dosage in this population. Close monitoring of hematologic parameters is advised.

**Hepatic Insufficiency:** There are no data that support specific guidance for dosage adjustment in patients with impaired hepatic function. Close monitoring of hematologic parameters is advised.

**INSTRUCTIONS FOR USE, HANDLING and DISPOSAL**

If the patient prefers, or is unable to swallow capsules, the contents of the capsules may be emptied into a glass of water and taken immediately (see PRECAUTIONS, Information for Patients). Some inert material used as a vehicle in the capsule may not dissolve, and float on the surface.

Patients who take the drug by emptying the contents of the capsule into water should be reminded that this is a potent medication that must be handled with care. Patients must be cautioned not to allow the powder to come in contact with the skin and mucous membranes, including avoidance of inhaling the powder when opening the capsules. People who are not taking HYDREA should not be exposed to it. To decrease the risk of exposure, wear disposable gloves when handling HYDREA or bottles containing HYDREA. Anyone handling HYDREA should wash their hands before and after contact with the bottle or capsules.

If the powder is spilled, it should be immediately wiped up with a damp disposable towel and discarded in a closed container, such as a plastic bag, as should the empty capsules. HYDREA should be kept away from children and pets.

To minimize the risk of dermal exposure, always wear impervious gloves when handling bottles containing HYDREA capsules. This includes handling activities in clinical settings, pharmacies, storerooms, and home healthcare settings, including during unpacking and inspection, transport within a facility, and dose preparation and administration.

Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published. There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.
PHARMACEUTICAL INFORMATION

I. Drug Substance
   Proper Name: Hydroxyurea

   \[
   \begin{align*}
   &O \\
   &\| \\
   &H_2N - C - NH - OH \\
   \end{align*}
   \]

   Structural Formula:
   Molecular formula: CH₄N₂O₂
   Molecular Weight: 76.05
   Description: Hydroxyurea is an essentially tasteless, white to off white crystalline powder, freely soluble in water and practically insoluble in alcohol.

II. Composition
   Each capsule contains 500 mg hydroxyurea, dibasic sodium phosphate, citric acid, magnesium stearate and lactose.

III. Stability and Storage Recommendations
   HYDREA (hydroxyurea) should be stored at room temperature (15 - 30°C). Protect from excessive heat and moisture.

AVAILABILITY OF DOSAGE FORMS
   HYDREA (hydroxyurea) is available in capsules with opaque green cap and opaque pink body printed with “BMS 303” in black ink on both body and cap contains 500 mg hydroxyurea. Bottles of 100.

PHARMACOLOGY

Animal
   Animal studies confirm that hydroxyurea is promptly and completely absorbed from the gastrointestinal tract. Studies with radioactive hydroxyurea administered orally or intraperitoneally to mice and rats showed that 75% of the radioactivity is recovered in the urine, with trace amounts found in the feces after 24 hours. 55% of the intraperitoneal dose in mice is metabolized to urea and carbon dioxide while 45% is excreted unchanged.

   Intravenous administration to rats showed that hydroxyurea is rapidly equilibrated throughout body fluids and is rapidly excreted in urine. Plasma concentration in this study was found to decay exponentially. The proportion of drug recovered in the urine increased with the dose
given.

Intravenous administration of a single dose of 100 mg/kg to a dog resulted in serum levels of 130, 110, 80 and 80 mcg/mL at 15, 30, 60 and 120 minutes respectively. Levels in the cerebrospinal fluid were 10, 20 and 30 mcg/mL at 30, 60 and 120 minutes, respectively.

**TOXICOLOGY**

<table>
<thead>
<tr>
<th>Species</th>
<th>Sex</th>
<th>Formulation</th>
<th>Route of Administration</th>
<th>LD₅₀ (g/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mice</td>
<td>M</td>
<td>10% in water</td>
<td>Oral</td>
<td>7.3</td>
</tr>
<tr>
<td>Mice</td>
<td>M/F</td>
<td>10% in water</td>
<td>Oral</td>
<td>5</td>
</tr>
<tr>
<td>Mice</td>
<td>M</td>
<td>10% in water</td>
<td>I.P.</td>
<td>7.3</td>
</tr>
<tr>
<td>Mice</td>
<td>M/F</td>
<td>10 - 12% in water</td>
<td>I.V.</td>
<td>&gt; 15</td>
</tr>
<tr>
<td>Rats</td>
<td>M</td>
<td>10 or 30% in water</td>
<td>Oral</td>
<td>5.8</td>
</tr>
<tr>
<td>Rats</td>
<td>M</td>
<td>10% in saline</td>
<td>I.V.</td>
<td>4.7</td>
</tr>
<tr>
<td>Dogs</td>
<td>M</td>
<td>Capsules</td>
<td>Oral</td>
<td>Not lethal at a dose of 2.0</td>
</tr>
<tr>
<td>Dogs</td>
<td>M/F</td>
<td>10% in saline</td>
<td>I.V.</td>
<td>Not lethal at doses of 0.1 - 4.0</td>
</tr>
</tbody>
</table>

Signs of toxicity in mice included: excitement followed by sedation, ataxia, tremors, convulsions.

In rats, toxicity was manifested by: excitement followed by sedation, tremors, ataxia, convulsions, loss of weight, rigidity, apnea.

Signs of toxicity in dogs were: panting, ataxia, defecation, emesis, unsteady gait, mydriasis, weakness of the hind limbs, hypothermia, bradycardia, decreased sensitivity to pain, loss of scratch reflex and eventually a plane 3 anesthesia.

**Subacute and Chronic Toxicity**

In subacute and chronic toxicity studies in the rat, the most consistent pathological findings were an apparent dose-related mild to moderate bone marrow hypoplasia as well as pulmonary congestion and mottling of the lungs. At the highest dosage levels (1260 mg/kg/day for 37 days then 2520 mg/kg/day for 40 days), testicular atrophy with absence of spermatogenesis occurred; in several animals, hepatic cell damage with fatty metamorphosis was noted. Thymic atrophy, weight depression and a tendency to bronchopulmonary infections were also noted. In the mouse, weight losses were more pronounced with daily therapy than with intermittent treatment.

In the dog, mild to marked bone marrow depression was a consistent finding except at the lower dosage levels. Additionally, at the higher dose levels (140-420 or 140-1260 mg/kg/week given during 3 or 7 days a week for 12 weeks), growth retardation, slightly increased blood glucose values and hemosiderosis of the liver or spleen were found; reversible spermatogenic arrest was noted. In the monkey, bone marrow depression, lymphoid atrophy of the spleen and degenerative changes in the epithelium of the small and large intestines were found. At the higher, often lethal, doses (400-800 mg/kg/day for 7-15 days), hemorrhage and congestion were found in the lungs, brain and urinary tract. Changes in heart rate, blood pressure, orthostatic hypotension, electrocardiogram changes, and slight hemolysis, and/or methemoglobinemia) were observed in some species of laboratory animals at doses exceeding those used clinically.
Effect on Reproduction and Mutagenesis
Studies on rats given aqueous solutions of hydroxyurea orally revealed temporarily decreased fertility in male Fo generation rats due to aspermatogenesis. In Fo generation female rats there were no drug induced adverse effects on implantation of the number of live fetuses, viability or lactation. The administration of hydroxyurea did not induce mutagenic responses.


CONSUMER INFORMATION

HYDREA®
(hydroxyurea capsules, USP)

This leaflet is a summary and will not tell you everything about HYDREA®. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

What the medication is used for:
Hydrea (hydroxyurea) is used to treat cancer of the head and neck (excluding the lips) in combination with radiation, as well as cancer of the skin and a type of blood cancer (resistant chronic myelocytic leukemia).

What it does:
HYDREA seems to interfere with the growth of cancer cells by preventing them from dividing.

When it should not be used:
HYDREA should not be used if:
- you have problems with your bone marrow (low blood count e.g. severe anemia)
- you are sensitive/allergic to hydroxyurea or any other component of this medication (See “What the important nonmedicinal ingredients are” in this leaflet). Tell your doctor if you think you have had an allergic reaction to any of these ingredients.

What the medicinal ingredient is:
Hydroxyurea.

What the important nonmedicinal ingredients are:
Citric acid, dibasic sodium phosphate, lactose and magnesium stearate.

What dosage forms it comes in:
HYDREA is available in capsules containing 500 mg hydroxyurea.

WARNINGS AND PRECAUTIONS

BEFORE you use HYDREA talk to your doctor or pharmacist if:
- you have problems with your kidney because the dose of HYDREA may need to be adjusted
- you are breast feeding. HYDREA can pass into your breast milk and harm your baby. Do not breast-feed if you are taking HYDREA.
- you have problems with low blood count or anemia
- you have received radiation therapy as this may increase your chances of developing redness of the skin if HYDREA is used with radiation treatment.
- you are pregnant or planning on becoming pregnant. HYDREA can harm the fetus when given to a pregnant woman. Women should avoid becoming pregnant while undergoing treatment with HYDREA.
- you are a male contemplating conception. HYDREA may cause an absence or low amount of sperm in the semen (sometimes these events are reversible) and damage DNA in your sperm. Therefore you should seek advice on sperm conservation prior to treatment with HYDREA and use safe contraceptive measures during and at least 1 year after therapy ends.
- you have HIV/AIDS and are receiving treatment as this can increase your chances of developing pancreatitis (inflammation of the pancreas) and liver problems.
- you are lactose intolerant.
- you recently received a vaccination or are scheduled for any vaccination. Patients taking HYDREA should not receive live vaccines.
- you are receiving treatment with interferon. Inflammation of the blood vessels of the skin, sometimes leading to formation of ulcers or death of the blood vessels has been reported mostly in patients who have received or are currently receiving interferon treatment.

INTERACTIONS WITH THIS MEDICATION

Make sure you talk to your doctor about any other conditions you may have and all other medications you are taking, including prescription, non-prescription, and herbal and/or natural products.

Concurrent use of hydroxyurea and other myelosuppressive agents or radiation therapy may increase the likelihood of bone marrow depression or other adverse events.

PROPER USE OF THIS MEDICATION

While you are using this medicine, your doctor may want you to drink extra fluids so that you will pass more urine. This will help prevent kidney problems and keep your kidneys working well.

Usual dose:
The dose of HYDREA will be different for different patients. The dose that is used may depend on a number of things, including what the medicine is being used for, your weight, and whether or not other medicines are also being taken. Follow your doctor’s orders.
Depending on your condition, the usual dose could be 80 mg/kg, or 20-30 mg/kg given orally. The dose and frequency will vary with your disease. Please follow your doctor’s orders.

**Overdose:**
If you think you may have taken more HYDREA than you should, talk to your doctor immediately or contact the Emergency room of the nearest hospital.

**Missed Dose:**
If you miss a dose of this medicine check with your doctor.

**SIDE EFFECTS AND WHAT TO DO ABOUT THEM**

Along with their needed effects, medicines like HYDREA can sometimes cause unwanted effects such as blood problems and other side effects.

The following information describes the most important side effects of which you should be aware. It is not a comprehensive list of all side effects. You should report any unusual symptoms to your doctor.

Check with your doctor if any of the following side effects occur:
- Inflammation in or around the mouth
- Loss of appetite.
- High fevers (≥39 °C)
- Nausea and vomiting.
- Diarrhea and constipation.
- Inflammation of the blood vessels of the skin, sometimes leading to formation of ulcers or death of the blood vessels has been reported mostly in patients who have received or are currently receiving interferon treatment.
- Rash, redness and ulceration in the face, skin or extremities. Any skin or nail changes.

Tell your doctor immediately if you have a high fever (≥39°C) within 6 weeks of taking HYDREA. The high fever can sometimes come with stomach, lung, muscle, liver, skin or heart problems.

Discontinue medication and check with your doctor if any of the following side effects occur:
- Lack of urination, severe muscle weakness, abnormal heart beat, and seizures (symptoms of tumour lysis syndrome)
- Yellowing of skin and eyes, feeling tired, stomach ache, nausea, diarrhea, no appetite, fever, headaches (symptoms of Hepatitis)
- Clay-colored or white stools, dark urine, inability to digest certain foods, itching, nausea or vomiting, pain in the right upper part of the abdomen, yellow skin or eyes (symptoms of cholestasis)

### SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Talk with your doctor or pharmacist</th>
<th>Stop taking drug and call your doctor or pharmacist</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Common</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouth sores</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>(inflammation in or around the mouth)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea and vomiting</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Diarrhea and constipation</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Yellowing of the skin and eyes, feeling tired, stomach ache, fever</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td><strong>Uncommon</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Loss of appetite</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Drowsiness, headache and dizziness</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Disorientation, hallucinations, and convulsions</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td><strong>Rare</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lack of urination, and seizures</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Skin redness, sores, and/or ulcers if you have been or, are currently being, treated with interferon.</td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

*This is not a complete list of side effects. For any unexpected effects while taking HYDREA, contact your doctor or pharmacist.*
**HOW TO STORE IT**

HYDREA should be stored at room temperature (15 – 30°C). Protect from heat and moisture.

**REPORTING SUSPECTED SIDE EFFECTS**

To monitor drug safety, Health Canada collects information on serious and unexpected effects of drugs. If you suspect you have had a serious or unexpected reaction to this drug you may notify Health Canada by:

- **toll-free telephone:** 866-234-2345
- **toll-free fax:** 866-678-6789
- **By email:** cadrmp@hc-sc.gc.ca

By regular mail:
National AR Centre
Marketed Health Products Safety and Effectiveness
Information Division
Marketed Health Products Directorate
Tunney’s Pasture, AL 0701C
Ottawa ON K1A 0K9

*NOTE: Before contacting Health Canada, you should contact your physician or pharmacist.*

**MORE INFORMATION**

This document plus the full product monograph, prepared for health professionals can be obtained by contacting the sponsor, Bristol-Myers Squibb Canada, at 1-866-463-6267.

This leaflet was prepared by Bristol Myers Squibb Canada.

Last revised: 26 September 2017

HYDREA is a registered of Bristol-Myers Squibb Canada Co.